




RealRate

PHARMACEUTICAL 2015

DNIB Unwind INC
Rank 154 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of DNIB Unwind INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DNIB Unwind INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 34% points. The greatest weakness of DNIB Unwind INC is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 256%, being 1.7% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	45,963
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,935
Liabilities, Non-Current	2,969
Other Assets	1,538
Other Compr. Net Income	-2,414
Other Expenses	0
Other Liabilities	0
Other Net Income	971
Other Revenues	10,426
Property and Equipment	6,567
Research and Development	28,874
Selling, General and Administrative Expense	15,060

Output Variable	Value in 1000 USD
Assets	54,068
Liabilities	16,904
Expenses	43,934
Revenues	10,426
Stockholders Equity	37,164
Net Income	-32,537
Comprehensive Net Income	-33,744
BaseVar	64,358
ECR before LimitedLiability	133%
Economic Capital Ratio	256%